Lexicon Pharmaceuticals, Inc.

NASDAQ:LXRX

Biotechnology

Healthcare
$1.72 -2.64%

-$0.05 today

Market cap
$765.80M
Beta
1.07
P/E (TTM)
-30.5
EPS (TTM)
-$0.07
52W Low $0.71High $2.53

Volume 2.02M

Average 2.48M

LXRX Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

Lexicon Pharmaceuticals, Inc.NASDAQ: LXRX

Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026

Selling, general & admin declines year over year

Q1 FY2026 selling, general & admin of $9.23M fell 20.5% year over year, ahead of the -61.3% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 5.4% from the prior quarter.

Context

  • Selling, general & admin amounted to 74.9% of revenue in FY2025, down 349.4 pp from a year earlier.
  • Selling, general & admin increased in 1 of the last 3 fiscal years.

What to watch

Whether selling, general & admin reaches the consensus estimate from 4 analysts of $37.35M (+0.1%) for the fiscal year ending Dec 2026, a step up from the -71.7% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$9.23M+5.4% QoQ
Last fiscal yearDec 2025
$37.32M-71.7% YoY
LTMMar 2026
$34.94M-61.3% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-20.5%-57.4%-36.9 pp
1 year-71.7%+0.1%+71.8 pp
3-year CAGR—+26.6%—
5-year CAGR+47.4%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

USD · from the income statement

Latest · FY2025
37.32M USD
Year-over-year change
-71.7%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How LXRX compares with its peers on the latest reported figures

  • LXRX's LTM Mar 2026 selling, general & admin of $34.94M is the 7th highest of the 11 companies compared; the peer median is $87.2M.
  • Its year-over-year change of -61.3% is the lowest of 11, against a peer median of +10.5%.
  • Selling, general & admin amounts to 50.2% of revenue for LXRX, versus a peer median of 43.8%.
LXRX Competitors Peer median
Selling, General & Admin for LXRX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026$584.98M +66.3%+37.9%61.0%
PTCTPTC Therapeutics, Inc.LTM Jun 2026$351.33M +8.3%+2.1%34.8%
BCRXBioCryst Pharmaceuticals, Inc.LTM Jun 2026$337.33M +6.9%+29.8%35.9%
MNKDMannKind CorporationLTM Mar 2026$173.21M +78.5%+16.4%48.0%
RIGLRigel Pharmaceuticals, Inc.LTM Mar 2026$118.84M +5.8%+1.0%39.6%
NMRANeumora Therapeutics, Inc. Common StockLTM Mar 2026$55.57M -17.1%+24.5%—
LXRXLexicon Pharmaceuticals, Inc.LTM Mar 2026$34.94M -61.3%—50.2%
ORICORIC Pharmaceuticals, Inc.LTM Mar 2026$33.29M +12.6%+9.8%—
OVIDOvid Therapeutics Inc.LTM Mar 2026$24.75M -6.4%-9.4%347.5%
TRVITrevi Therapeutics, Inc.LTM Sep 2026$19.78M +34.5%+16.3%—
DMACDiaMedica Therapeutics Inc.LTM Mar 2026$9.79M +21.7%+16.7%—
Peer median (excluding LXRX) $87.2M+10.5%+16.3%43.8%

Competitors are the stored peer set for LXRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue298K139K1.2M31.08M49.8M
Cost of Revenue55.05M52.52M58.97M616K274K
Gross Profit(54.75M)(52.38M)(57.77M)30.47M49.53M
Gross Margin-18371.8%-37681.3%-4798.0%98.0%99.4%
Research & Development55.05M52.82M58.89M84.48M61.12M
Selling, General & Admin000131.9M37.32M
Operating Expenses32.34M48.38M113.98M227.58M98.44M
Depreciation & Amortization292K427K554K534K621K
EBITDA(86.66M)(100.03M)(169.76M)(184.29M)(41.38M)
EBITDA Margin-29081.9%-71966.2%-14099.3%-592.9%-83.1%
Operating Income(87.09M)(100.76M)(171.75M)(197.12M)(48.91M)
Operating Margin-29224.8%-72489.2%-14265.0%-634.2%-98.2%
Interest Income134K1.6M7.73M12.29M6.91M
Interest Expense802K2.78M13.1M15.58M8.34M
Other Income / Expenses(668K)(1.18M)(5.37M)(3.29M)(1.43M)
Income Before Tax(87.76M)(101.94M)(177.12M)(200.4M)(50.34M)
Pre-Tax Margin-29449.0%-73341.0%-14710.9%-644.8%-101.1%
Income Tax Expense00000
Net Income(87.76M)(101.94M)(177.12M)(200.4M)(50.34M)
Net Margin-29449.0%-73341.0%-14710.9%-644.8%-101.1%
EPS (Basic)(0.61)(0.62)(0.80)(0.63)(0.14)
EPS (Diluted)(0.61)(0.62)(0.80)(0.63)(0.14)
Weighted Avg Shares145.65M165.73M221.13M320.03M363.05M
Weighted Avg Shares (Diluted)145.65M165.73M221.13M320.03M363.05M

Lexicon Pharmaceuticals, Inc.

NASDAQ:LXRX

Intrinsic Alpha fair value

Locked

Current Price

$1.72

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.